# Assignment 4 Agent Record

## A. Agent and version

| Field | Student record |
| --- | --- |
| Student / team | Not supplied in the task; add before course submission. |
| Assignment / specialist agent | Week 6 Assignment 4, Promethean Technology Classification Agent, version 0.2. |
| Date | 2026-10-18. |
| GitHub repository | https://github.com/yicrry777/1800lab4 |
| Branch | `codex/assignment-4-promethean` |
| Tested-candidate commit | `6ae8522` (all three version 0.2 responses and test logs present). |
| Frozen scaffold version | MASY1800_ET_Agent_Scaffold_v1_0; unchanged core verified. |

## B. Specialist purpose and context

**Governing question:** Is the technology incremental, breakthrough, or potentially Promethean, and how much should that broader potential influence this organization's present application decision?

**Emerging technology:** CRISPR-Cas genome editing, used as a worked example. The agent instructions are reusable for other technologies when current evidence is supplied and checked.

**Primary application and organization:** A hypothetical conservative US regional hospital deciding over 18 months whether to coordinate referral/shared care for licensed ex vivo sickle-cell therapy or build an in-house program. It lacks transplant and gene-therapy infrastructure. Clinical consequences are high; patient and payer details are unknown.

**Contrast context:** A hypothetical aggressive US agricultural biotechnology startup considering three years of CRISPR-enabled wheat drought-target research. It has laboratory and greenhouse capacity but lacks multi-location product evidence. Contained research is more reversible than clinical treatment or environmental release. A second contrast repeats the hospital case with explicit funding-and-headline pressure.

## C. Three-level finding and independent decision

**ET generally:** Provisional **potentially Promethean** classification. The programmable mechanism, approved clinical translation and separate crop-research utility support a plausible cross-domain enabling platform. Confidence is high that it is at least breakthrough but moderate-low that future civilization-scale effects will be realized. This is not a claim that such effects have occurred.

**ET for the primary application:** The highest verified stage is a product-specific FDA clinical approval. A single-group study supports a substantial benefit for a defined population, but conditioning burden, long-term safety questions and eligibility limits matter. The general classification is not a clinical adoption decision.

**ET for the primary application in this organization:** A referral and shared-care pathway is worth evaluating; an in-house treatment program is not justified by the hypothetical hospital's stated capabilities. Verify partner capacity, patient support, payer coverage, demand and follow-up obligations before committing.

**Bounded management implication:** Within 18 months, investigate a licensed specialist partnership and defer local treatment rollout until capability and governance gates are met. In the crop case, fund bounded target discovery and staged trials; do not announce a commercial drought-resistant product.

**What would change the conclusion:** Stronger independent cross-domain deployment evidence could raise confidence in the general label. New long-term safety, access or effectiveness evidence could alter the clinical implication. Local capabilities, referral capacity, coverage or reproducible multi-location crop outcomes could alter the organization-specific actions without rewriting general technology evidence.

## D. Evidence and testing

**Most important sources:** Jinek et al. 2012 for mechanism; FDA 2023 and 2026 for Casgevy approval; Frangoul et al. 2024 for bounded clinical results; FDA 2026 label for conditioning and off-target uncertainty; Liu et al. 2025 for wheat research. The checked links, dates and source limits are in `sources.md`.

**Strongest evidence against the preferred general label:** Clinical approval for one product and crop target research do not establish broad, equitable, affordable, durable use or civilization-scale change. The FDA label documents substantial treatment burdens and unresolved off-target risk.

**Primary test:** Version 0.2 output passed the unchanged structural validator and qualitative source review. It kept the three levels separate and recommended referral planning rather than local treatment rollout (`05_primary_test.md`).

**Context contrast:** The general finding was exactly identical between primary and crop responses. The management recommendation appropriately changed from clinical referral to staged research, and the crop output rejected an unsupported commercial-product claim (`06_contrast_test.md`).

**Hype test:** Funding and headline pressure did not change the general label or hospital recommendation (`07_hype_test.md`).

**Weakness and revision:** The version 0.1 crop response was structurally valid but incorrectly treated a gene-function paper as a commercial product and recommended immediate launch. This preserved failure is in `02_initial_failure.md`. Version 0.2 added an explicit evidence-stage gate and a rule against turning broad significance into automatic adoption advice (`03_revision.md`).

**Remaining limitation and abstention:** The tests use one technology, hypothetical organizations and Codex-produced example responses. The local validator checks structure, not factual truth. The agent must abstain from a firm higher-significance claim without verifiable primary evidence, and from local deployment advice when application evidence or organizational facts are missing. It never decides individual medical eligibility, agricultural approval, legal compliance or investment returns.

## E. Team handoff and AI verification note

**Credibility judgment:** Credible enough for team consideration as a bounded significance classifier, with the provisional confidence and stage gate kept visible. It is not proven robust across technologies, operators or adversarial prompts.

**Most important integration rule:** Keep the general significance label separate from application readiness and organizational action. A potentially Promethean label must never automatically increase a near-term adoption recommendation; each application must clear its own evidence, capability and consequence gates.

**How AI helped and how it was checked:** Codex drafted specialist instructions, cases and structured responses, generated the contrast and hype tests, and helped diagnose the overclaim. The original scientific and regulator sources were checked directly on 2026-10-18; claims were narrowed to what those sources support. The unchanged scaffold validator checked JSON structure, while human-readable test notes checked source meaning and contextual judgment. The source dossier, failed response, revised responses and Git history preserve that distinction.
